Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Cyclacel Pharmaceuticals’ next clinical milestone can feel like hunting for needles in a 300-page stack of SEC disclosures. The company’s filings brim with dense oncology science—CDK2/9 dosing data for fadraciclib, PLK1 safety cohorts for plogosertib—and intricate financing terms tied to its CYCCP preferred shares. Finding trial timelines, cash runway, or Cyclacel Pharmaceuticals insider trading Form 4 transactions shouldn’t require a PhD or hours of scrolling.
Stock Titan closes that gap. Our platform delivers AI-powered summaries that turn every 10-K, 10-Q, 8-K, or S-3 into plain English bullet points, then links you straight to the source page. Whether you search “Cyclacel Pharmaceuticals quarterly earnings report 10-Q filing” or “understanding Cyclacel Pharmaceuticals SEC documents with AI,” you’ll see trial costs, dilution impact, and risk factors highlighted in context. Real-time alerts surface Cyclacel Pharmaceuticals Form 4 insider transactions real-time, so you know the moment executives buy or sell.
Wondering where the next catalyst hides? Use our quick-view cards to jump to:
- 10-K & 10-Q – cash runway, R&D spend, and drug pipeline status in one click (Cyclacel Pharmaceuticals annual report 10-K simplified).
- 8-K – trial data drops and financing deals (Cyclacel Pharmaceuticals 8-K material events explained).
- Form 4 – executive stock moves (Cyclacel Pharmaceuticals executive stock transactions Form 4).
- DEF 14A – Cyclacel Pharmaceuticals proxy statement executive compensation snapshots.
No more decoding biotech jargon—just actionable insights like Cyclacel Pharmaceuticals earnings report filing analysis delivered as soon as the document hits EDGAR. Explore every CYCCP disclosure, clarified and searchable, today.
Cyclacel Pharmaceuticals reporting persons Armistice Capital, LLC and Steven Boyd state they do not beneficially own any shares of Cyclacel common stock. The filing discloses 0 shares and 0% ownership, and explains that Armistice Capital acts as investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. The statement clarifies that the Master Fund disclaims beneficial ownership because it lacks voting and dispositive power under its investment management agreement, while Armistice and Mr. Boyd may be deemed to possess voting and investment power through that agreement. The ownership percentages are calculated using 1,583,965 shares reported outstanding in the issuer's S-1.
Cyclacel Pharmaceuticals disclosed that it is presenting audited consolidated financial statements for the quarter ended March 31, 2025 to satisfy the eligibility requirements of a registration statement on Form S-3. The filing indicates the company is providing its audited quarter-end financials and related notes so it meets the stated Form S-3 condition for shelf or registered offerings.
The report lists two exhibits: Exhibit 99.1 (the audited financial statements for the quarter) and Exhibit 104 (the cover page interactive XBRL data). The filing itself does not include income statement, balance sheet, or management discussion figures within the report text provided.
On 08/08/2025, investor David E. Lazar filed Amendment No. 2 to Schedule 13D for Cyclacel Pharmaceuticals, Inc. (CUSIP 23254L801). The filing states that, as of the close of business 08/05/2025, Lazar no longer beneficially owns any shares of Cyclacel’s common stock. Based on the company’s reported 1,583,965 shares outstanding as of 07/10/2025 (per the 07/30/2025 Form S-1), his ownership is now 0 shares / 0 %.
Accordingly, this amendment is designated as a final “exit” filing; all voting and dispositive powers are listed as zero. Exhibit 1 (not included here) details transactions within the past 60 days, but the cover page confirms that no shares remain. No other material agreements, legal proceedings, or changes were disclosed.
Schedule 13D/A (Amendment 1) for Cyclacel Pharmaceuticals (CYCC, CYCCP) updates the beneficial ownership of former CEO David E. Lazar.
- Current stake: 129,629 common shares, representing 8.18% of the 1,583,965 shares outstanding as of 10 Jul 2025.
- Recent corporate actions: Cyclacel effected a 1-for-15 reverse stock split on 7 Jul 2025; share numbers in this filing are post-split.
- Ownership changes: On 26 Feb 2025 Lazar converted his preferred stock to common and sold 194,628,820 common shares (pre-split) to a third-party investor. Earlier filings overstated the preferred shares he retained; this amendment corrects that error.
- Governance update: Lazar resigned as Chief Executive Officer effective 2 Apr 2025 but remains a significant shareholder with sole voting and dispositive power over the reported shares.
No group affiliation, financing source identified as PF (personal funds), and no legal proceedings or additional arrangements beyond those disclosed.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
